

# Olivier Hermine

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8413772/olivier-hermine-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

235  
papers

9,054  
citations

49  
h-index

92  
g-index

245  
ext. papers

11,458  
ext. citations

6.4  
avg, IF

5.6  
L-index

#	Paper	IF	Citations
235	Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. <i>New England Journal of Medicine</i> , <b>2002</b> , 347, 89-94	59.2	651
234	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 32-40	11.5	407
233	Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 453-9	2.2	406
232	Caspase activation is required for terminal erythroid differentiation. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 193, 247-54	16.6	338
231	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2530-41	59.2	269
230	Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. <i>PLoS ONE</i> , <b>2009</b> , 4, e7258	3.7	268
229	Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. <i>Journal of Investigative Dermatology</i> , <b>2010</b> , 130, 804-15	4.3	264
228	Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4177-83	2.2	261
227	Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. <i>Lancet, The</i> , <b>2016</b> , 388, 545-55	40	233
226	Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. <i>New England Journal of Medicine</i> , <b>1995</b> , 332, 1749-51	59.2	226
225	ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?. <i>Frontiers in Aging Neuroscience</i> , <b>2017</b> , 9, 68	5.3	219
224	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 35-45	11.5	209
223	Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. <i>Nature</i> , <b>2007</b> , 445, 102-5	50.4	199
222	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , <b>2017</b> , 77, 1261-1270	10.1	162
221	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 499-518	27.4	154
220	Arsenic Trioxide and Interferon- $\gamma$ Synergize to Induce Cell Cycle Arrest and Apoptosis in Human T-Cell Lymphotropic Virus Type III-transformed Cells. <i>Blood</i> , <b>1999</b> , 93, 278-283	2.2	150
219	Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). <i>Blood</i> , <b>2009</b> , 113, 6528-32	2.2	147

218	Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 202-8	2.2	138
217	Mast cell leukemia. <i>Blood</i> , <b>2013</b> , 121, 1285-95	2.2	124
216	Gain-of-function mutations in the extracellular domain of KIT are common in canine mast cell tumors. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1137-45	6.6	124
215	How I treat adult T-cell leukemia/lymphoma. <i>Blood</i> , <b>2011</b> , 118, 1736-45	2.2	116
214	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 295-304	35.1	116
213	Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Blood</i> , <b>2016</b> , 128, 2527-2532	2.2	115
212	Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3264-74	2.2	111
211	Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. <i>The Hematology Journal</i> , <b>2004</b> , 5, 130-4		110
210	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 1125-1133.e1	5.4	106
209	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , <b>2015</b> , 126, 604-11	2.2	104
208	Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. <i>Alzheimer's Research and Therapy</i> , <b>2011</b> , 3, 16	9	99
207	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 677-687	2.2	94
206	Autoantibodies neutralizing type I IFNs are present in 4% of uninfected individuals over 70 years old and account for 20% of COVID-19 deaths. <i>Science Immunology</i> , <b>2021</b> , 6,	28	91
205	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , <b>2013</b> , 121, 2393-401	2.2	89
204	A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. <i>The Hematology Journal</i> , <b>2002</b> , 3, 276-82		89
203	Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). <i>Lancet Infectious Diseases</i> , <b>2016</b> , 16, 606-617	25.5	89
202	HSP70 sequestration by free h-globin promotes ineffective erythropoiesis in thalassaemia. <i>Nature</i> , <b>2014</b> , 514, 242-6	50.4	85
201	Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. <i>Blood</i> , <b>2015</b> , 126, 1009-16; quiz 1050	2.2	85

200	Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , <b>2016</b> , 13, 177	10.1	84
199	Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. <i>BMC Neurology</i> , <b>2012</b> , 12, 36	3.1	80
198	Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. <i>Journal of Experimental Medicine</i> , <b>2021</b> , 218,	16.6	79
197	In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. <i>Blood</i> , <b>2012</b> , 120, 4846-9	2.2	77
196	Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. <i>Blood</i> , <b>2018</b> , 131, 417-420	2.2	75
195	Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. <i>Journal of Experimental Medicine</i> , <b>2010</b> , 207, 2785-92	16.6	73
194	Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. <i>Lancet, The</i> , <b>2017</b> , 389, 612-620	4.0	72
193	Ineffective erythropoiesis in $\beta$ -thalassemia. <i>Scientific World Journal, The</i> , <b>2013</b> , 2013, 394295	2.2	67
192	Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2020</b> , 21, 5-14	3.6	64
191	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. <i>Leukemia</i> , <b>2019</b> , 33, 1687-1699	10.7	57
190	Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. <i>Blood</i> , <b>2006</b> , 108, 1065-72	2.2	54
189	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 474-90	3.8	52
188	Molecular defects in mastocytosis: KIT and beyond KIT. <i>Immunology and Allergy Clinics of North America</i> , <b>2014</b> , 34, 239-62	3.3	52
187	Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1241-1243	11.5	52
186	SRSF2-p95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes. <i>Haematologica</i> , <b>2014</b> , 99, 830-5	6.6	49
185	A Review of New Findings in Adult T-cell Leukemia-Lymphoma: A Focus on Current and Emerging Treatment Strategies. <i>Advances in Therapy</i> , <b>2018</b> , 35, 135-152	4.1	46
184	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , <b>2016</b> , 101, 1133-1143	6.6	46
183	Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> , <b>1996</b> , 13 Suppl 1, S186-90		45

182	Spherocytic shift of red blood cells during storage provides a quantitative whole cell-based marker of the storage lesion. <i>Transfusion</i> , <b>2017</b> , 57, 1007-1018	2.9	40
181	Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. <i>Cancer Letters</i> , <b>2014</b> , 349, 120-7	9.9	40
180	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. <i>Haematologica</i> , <b>2016</b> , 101, 336-45	2.2	40
179	Rituximab Maintenance after Autologous Stem Cell Transplantation Prolongs Survival in Younger Patients with Mantle Cell Lymphoma: Final Results of the Randomized Phase 3 LyMa Trial of the Lysa/Goelams Group. <i>Blood</i> , <b>2016</b> , 128, 145-145	6.6	37
178	Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. <i>PLoS ONE</i> , <b>2014</b> , 9, e103405	2.2	35
177	Early High-Dose Erythropoietin Therapy After Out-of-Hospital Cardiac Arrest: A Multicenter, Randomized Controlled Trial. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 40-9	3.7	33
176	Adult T cell leukaemia: a review of established and new treatments. <i>BioDrugs</i> , <b>1998</b> , 10, 447-62	15.1	31
175	Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?. <i>Viruses</i> , <b>2011</b> , 3, 750-69	7.9	31
174	NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC study. <i>Gut</i> , <b>2019</b> , 68, 1396-1405	6.2	29
173	Feline low-grade alimentary lymphoma: an emerging entity and a potential animal model for human disease. <i>BMC Veterinary Research</i> , <b>2018</b> , 14, 306	19.2	29
172	Spectrum and Prognosis of Noninfectious Renal Mixed Cryoglobulinemic GN. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2016</b> , 27, 1213-24	2.7	29
171	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1223-1230	12.7	27
170	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. <i>Wiener Klinische Wochenschrift</i> , <b>2012</b> , 124, 807-14	2.2	27
169	Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 35, 501-5	2.3	26
168	Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2017</b> , 35, 864-868	1.9	26
167	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , <b>2016</b> , 6, 972-85	1.3	25
166	The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 81-87	24.4	24
165		5.4	24

164	Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector. <i>Blood</i> , <b>2015</b> , 126, 202-202	2.2	23
163	Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas. <i>Blood</i> , <b>2016</b> , 128, 4164-4164	2.2	22
162	Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0162965	3.7	22
161	Regulation of globin-heme balance in Diamond-Blackfan anemia by HSP70/GATA1. <i>Blood</i> , <b>2019</b> , 133, 1358-1370	2.2	21
160	Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2387-2395.e3	5.4	21
159	Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2315-2324	2.2	21
158	Eighty percent of French sport winners in Olympic, World and Europeans competitions have mutations in the hemochromatosis HFE gene. <i>Biochimie</i> , <b>2015</b> , 119, 1-5	4.6	20
157	Prevalence and risk factors for fragility fracture in systemic mastocytosis. <i>Bone</i> , <b>2017</b> , 105, 219-225	4.7	20
156	Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma. <i>Methods in Molecular Biology</i> , <b>2017</b> , 1582, 197-216	1.4	19
155	The severe phenotype of Diamond-Blackfan anemia is modulated by heat shock protein 70. <i>Blood Advances</i> , <b>2017</b> , 1, 1959-1976	7.8	19
154	Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 1207	5.7	17
153	Telangiectasia macularis eruptiva perstans (TMEP): A form of cutaneous mastocytosis with potential systemic involvement. <i>Journal of the American Academy of Dermatology</i> , <b>2016</b> , 74, 885-91.e1	4.5	17
152	Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts. <i>Current Hematologic Malignancy Reports</i> , <b>2016</b> , 11, 416-424	4.4	17
151	Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 616-624	4.5	16
150	Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon- $\beta$ . <i>Blood Advances</i> , <b>2017</b> , 1, 748-752	7.8	16
149	Targeted Treatment Options in Mastocytosis. <i>Frontiers in Medicine</i> , <b>2017</b> , 4, 110	4.9	16
148	In Situ Hepatitis C NS3 Protein Detection Is Associated with High Grade Features in Hepatitis C-Associated B-Cell Non-Hodgkin Lymphomas. <i>PLoS ONE</i> , <b>2016</b> , 11, e0156384	3.7	16
147	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. <i>Oncotarget</i> , <b>2017</b> , 8, 52256-52268	3.3	16

146	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 356-366.e4	11.5	15
145	Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1927-1938	9.3	15
144	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Interim Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , <b>2015</b> , 126, 338-338	2.2	15
143	Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. <i>Leukemia</i> , <b>2020</b> , 34, 1462-1466	10.7	15
142	Rapid clearance of storage-induced microerythrocytes alters transfusion recovery. <i>Blood</i> , <b>2021</b> , 137, 2285-2298	2.2	15
141	A toxic palmitoylation of Cdc42 enhances NF- $\kappa$ B signaling and drives a severe autoinflammatory syndrome. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 1201-1204.e8	11.5	15
140	Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1782-1788	1.9	14
139	R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. <i>Blood</i> , <b>2010</b> , 116, 965-965	2.2	13
138	Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study. <i>European Journal of Haematology</i> , <b>2019</b> , 102, 63-69	3.8	13
137	High concentration of topical amitriptyline for treating chemotherapy-induced neuropathies. <i>Supportive Care in Cancer</i> , <b>2019</b> , 27, 3053-3059	3.9	13
136	Hepatitis C virus - Associated marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , <b>2017</b> , 30, 41-49	4.2	12
135	Physical health conditions and quality of life in adults with primary immunodeficiency diagnosed during childhood: A French Reference Center for PIDs (CEREDIH) study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1275-1281.e7	11.5	12
134	Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma?: a Retrospective Study From the Lymphoma Working Party of the EBMT. <i>Blood</i> , <b>2010</b> , 116, 688-688	2.2	12
133	Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. <i>Science Translational Medicine</i> , <b>2021</b> , eabj7521	17.5	12
132	Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry. <i>Leukemia</i> , <b>2020</b> , 34, 1090-1101	10.7	12
131	Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin. <i>Cell Reports</i> , <b>2019</b> , 26, 3246-3256.e4	10.6	11
130	Novel Treatments of Adult T Cell Leukemia Lymphoma. <i>Frontiers in Microbiology</i> , <b>2020</b> , 11, 1062	5.7	11
129	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. <i>Cell Reports</i> , <b>2020</b> , 30, 739-754.e4	10.6	11

128	Comparative oncology: The paradigmatic example of canine and human mast cell neoplasms. <i>Veterinary and Comparative Oncology</i> , <b>2019</b> , 17, 1-10	2.5	11
127	MRD Eradication Should be the Therapeutic Goal in Mantle Cell Lymphoma and May Enable Tailored Treatment Approaches: Results of the Intergroup Trials of the European MCL Network. <i>Blood</i> , <b>2014</b> , 124, 147-147	2.2	11
126	A Single-Tube, EuroClonality-Inspired, TRG Clonality Multiplex PCR Aids Management of Patients with Enteropathic Diseases, including from Formaldehyde-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , <b>2019</b> , 21, 111-122	5.1	11
125	Effects of Chronic Masitinib Treatment in APPswe/PSEN1dE9 Transgenic Mice Modeling Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 76, 1339-1345	4.3	10
124	Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2014</b> , 944, 175-81	3.2	10
123	ATL treatment: is it time to change?. <i>Blood</i> , <b>2015</b> , 126, 2533-4	2.2	10
122	Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial. <i>Nature Medicine</i> , <b>2021</b> ,	50.5	10
121	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. <i>Blood</i> , <b>2018</b> , 132, 163-163	2.2	10
120	Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients. <i>Blood</i> , <b>2010</b> , 116, 1982-1982	2.2	10
119	Arsenic trioxide (AsO) as a maintenance therapy for adult T cell leukemia/lymphoma. <i>Retrovirology</i> , <b>2020</b> , 17, 5	3.6	9
118	Fluorescence Exclusion: A Simple Method to Assess Projected Surface, Volume and Morphology of Red Blood Cells Stored in Blood Bank. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 164	4.9	9
117	Recent advances in the understanding and therapeutic management of mastocytosis. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	9
116	Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis. <i>Theranostics</i> , <b>2021</b> , 11, 292-303	12.1	9
115	Neuropilin-1 peptide-like ligands with proline mimetics, tested using the improved chemiluminescence affinity detection method. <i>MedChemComm</i> , <b>2019</b> , 10, 332-340	5	8
114	New Peptides Structurally Related to VEGF-A165 Exon-7 and -8 Encoded Domains Antagonize Its Binding to NRP-1 and VEGF-R1. <i>International Journal of Peptide Research and Therapeutics</i> , <b>2015</b> , 21, 117-124	2.1	8
113	Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. <i>Frontiers in Microbiology</i> , <b>2018</b> , 9, 925	5.7	8
112	Association of mastocytosis with inflammatory joint diseases: a series of 31 patients. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 362-5	5.3	8
111	A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival. <i>Blood</i> , <b>2016</b> , 128, 1158-1159	2.2	8



110	Improving the diagnostic efficiency of primary immunodeficiencies with targeted next-generation sequencing. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 734-737	11.5	8
109	Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS). <i>British Journal of Haematology</i> , <b>2019</b> , 184, 472-475	4.5	7
108	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T phase IB trial of the LYSA. <i>Annals of Hematology</i> , <b>2020</b> , 99, 1771-1778	3	6
107	Hydroxychloroquine as a novel therapeutic approach in mast cell activation diseases. <i>Clinical Immunology</i> , <b>2018</b> , 194, 75-79	9	6
106	Urea moiety as amide bond mimetic in peptide-like inhibitors of VEGF-A/NRP-1 complex. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2019</b> , 29, 2493-2497	2.9	5
105	Metabolic rejuvenation upgrades circulatory functions of red blood cells stored under blood bank conditions. <i>Transfusion</i> , <b>2021</b> , 61, 903-918	2.9	5
104	Predictive Power of FDG-PET Parameters at Diagnosis and after Induction in Patients with Mantle Cell Lymphoma, Interim Results from the LyMa-PET Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , <b>2015</b> , 126, 335-335	2.2	5
103	Anti-Lymphoma Activity of Interferon-Free Antiviral Treatment in Patients with Indolent B-Cell Lymphomas Associated with Hepatitis C Virus Infection. <i>Blood</i> , <b>2015</b> , 126, 3938-3938	2.2	5
102	2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	5
101	Dual cytoplasmic and nuclear localization of HTLV-1-encoded HBZ protein is a unique feature of adult T-cell leukemia. <i>Haematologica</i> , <b>2021</b> , 106, 2076-2085	6.6	5
100	Atypical splice-site mutations causing VEXAS syndrome. <i>Rheumatology</i> , <b>2021</b> , 60, e435-e437	3.9	5
99	Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis. <i>Leukemia</i> , <b>2021</b> ,	10.7	5
98	TCL1 expression patterns in Waldenström macroglobulinemia. <i>Modern Pathology</i> , <b>2016</b> , 29, 83-8	9.8	4
97	A neuropathological study of cerebrovascular abnormalities in a signal transducer and activator of transcription 3-deficient patient. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1418-21.e1-5	11.5	4
96	Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2170-2179	4.4	4
95	Storage-Induced Micro-Erythrocytes Are Rapidly Cleared from Recipient Circulation and Predict Transfusion Recovery. <i>Blood</i> , <b>2019</b> , 134, 717-717	2.2	4
94	A Worldwide Meta-Analysis on the Use of Zidovudine and Interferon-alpha for the Treatment of Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 2049-2049	2.2	4
93	Tumor Cell Proliferation (Ki-67 Index) Overcomes Cytology and Growth Pattern As Prognostic Factor in Mantle-Cell Lymphoma [Results from Randomized Trials of the European MCL Network. <i>Blood</i> , <b>2014</b> , 124, 2977-2977	2.2	4

92	Masitinib in nonresectable pancreatic cancer: Results of a phase III randomized placebo-controlled trial.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 158-158	2.2	4
91	Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2021</b> , 14, 17562864211030365	6.6	4
90	Neurological Involvement in Childhood Evans Syndrome. <i>Journal of Clinical Immunology</i> , <b>2019</b> , 39, 171-181	3.7	3
89	Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies. <i>Haematologica</i> , <b>2020</b> , 105, e461-464	6.6	3
88	Does Cysteine Rule (CysR) Complete the CendR Principle? Increase in Affinity of Peptide Ligands for NRP-1 Through the Presence of N-Terminal Cysteine. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	3
87	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. <i>Blood</i> , <b>2020</b> , 136, 8-9	2.2	3
86	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in $\beta$ Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. <i>Blood</i> , <b>2020</b> , 136, 45-46	2.2	3
85	FGFR3 Tyrosine Kinase Inhibitor AB1010 as Treatment of t(4;14) Multiple Myeloma.. <i>Blood</i> , <b>2007</b> , 110, 413-413	2.2	3
84	Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program.. <i>Blood</i> , <b>2010</b> , 116, 1794-1794	2.2	3
83	Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Long-Term Follow-up of the Randomized, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma Network. <i>Blood</i> , <b>2021</b> , 138, 380-380	2.2	3
82	Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1705-1712.e4	5.4	3
81	Criteria for the Regression of Pediatric Mastocytosis: A Long-Term Follow-Up. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1695-1704.e5	5.4	3
80	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119, e2200413119 <sup>11.5</sup>	11.5	3
79	Congenital Neutropenia Is Also Associated with a High Cancer Risk: A Study from the French Severe Chronic Neutropenia Registry. <i>Blood</i> , <b>2020</b> , 136, 15-16	2.2	2
78	UBA1 gene mutation in giant cell arteritis.. <i>Clinical Rheumatology</i> , <b>2022</b> , 41, 1257	3.9	2
77	High Response Rate After 4 Courses of R-DHAP In Untreated Mantle Cell Lymphoma (MCL) Patients In the Ongoing Phase III Randomized GOELAMS and GELA LyMa Trial. <i>Blood</i> , <b>2010</b> , 116, 1758-1758	2.2	2
76	XPO1 (Exportin-1) Is a Major Regulator of Human Erythroid Differentiation. Potential Clinical Applications to Decrease Ineffective Erythropoiesis of Beta-Thalassemia. <i>Blood</i> , <b>2015</b> , 126, 2368-2368	2.2	2
75	Masitinib in imatinib-naive advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10089-10089	2.2	2

74	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3526-3526	2.2	2
73	Urea-Peptide Hybrids as VEGF-A/NRP-1 Complex Inhibitors with Improved Receptor Affinity and Biological Properties. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 22,	6.3	2
72	Impact of Donor-Derived Invariant Natural Killer T (iNKT) Cell Reconstitution After Allogeneic Haematopoietic Stem Cell Transplantation.. <i>Blood</i> , <b>2009</b> , 114, 346-346	2.2	2
71	Hepatitis B virus-associated B-cell non-Hodgkin lymphoma in non-endemic areas in Western Europe: Clinical characteristics and prognosis. <i>Journal of Infection</i> , <b>2020</b> , 80, 219-224	18.9	2
70	Idelalisib treatment prior to allogeneic stem cell transplantation for patients with chronic lymphocytic leukemia: a report from the EBMT chronic malignancies working party. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 605-613	4.4	2
69	Loss of interleukin-10 activates innate immunity to eradicate adult T-cell leukemia-initiating cells. <i>Haematologica</i> , <b>2021</b> , 106, 1443-1456	6.6	2
68	Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia/lymphoma exposed to zidovudine and interferon alfa. <i>Annals of Hematology</i> , <b>2021</b> , 100, 2813-2824	2.2	2
67	The association of Greig syndrome and mastocytosis reveals the involvement of the hedgehog pathway in advanced mastocytosis. <i>Blood</i> , <b>2021</b> , 138, 2396-2407	2.2	2
66	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
65	Neuroinflammatory disorders and mastocytosis: A possible association?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 2878-2881.e1	5.4	1
64	Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. <i>Blood</i> , <b>2020</b> , 136, 12-13	2.2	1
63	Effective anti-SARS-CoV-2 immune response in patients with clonal mast cell disorders.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,	5.4	1
62	Modulation of Activin Signaling by RAP-011 (ActRIIA-IgG1) Improve Anemia, Increases Hemoglobin Levels and Corrects Ineffective Erythropoiesis in $\beta$ -Thalassemia. <i>Blood</i> , <b>2012</b> , 120, 247-247	2.2	1
61	The Spectrum Of Cold Agglutinin Disease At The Era Of Rituximab: A Retrospective Study On 48 Patients. <i>Blood</i> , <b>2013</b> , 122, 2193-2193	2.2	1
60	Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T3 Phase IB Trial of the Lysa Group. <i>Blood</i> , <b>2016</b> , 128, 2987-2987	2.2	1
59	BID Cleavage Pattern Is a Novel Check-Point That Determines the Fate of Human Erythroid Progenitors (Differentiation or Apoptosis. <i>Blood</i> , <b>2016</b> , 128, 397-397	2.2	1
58	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4027-4027	2.2	1
57	Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities. <i>Current Oncology Reports</i> , <b>2021</b> , 23, 141	6.3	1

56	Clinical, laboratory and ultrasonographic findings differentiating low-grade intestinal T-cell lymphoma from lymphoplasmacytic enteritis in cats. <i>Journal of Veterinary Internal Medicine</i> , <b>2021</b> ,	3.1	1
55	High-Resolution Whole-Genome Copy Number Profiling Identifies High-Risk and Low-Risk Patients with Mantle Cell Lymphoma, a Result of the Lyma-Genomic Project Conducted on Behalf the Lysa Group. <i>Blood</i> , <b>2016</b> , 128, 1745-1745	2.2	1
54	A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS8613-TPS8613	2.2	1
53	Substitution of opioids by N-methyl-D-aspartate receptor antagonists for treating pain in mastocytosis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2021</b> , 126, 293-295	3.2	1
52	Tocilizumab in Treatment for Patients With COVID-19-Reply. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1020-1021	1.5	1
51	GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness. <i>Blood</i> , <b>2021</b> , 138, 1590-1602	2.2	1
50	Biallelic mutations in the gene presenting as congenital sideroblastic anemia. <i>Haematologica</i> , <b>2021</b> , 106, 3202-3205	6.6	1
49	Absence of severe COVID-19 in patients with clonal mast cells activation disorders: effective anti-SARS-CoV-2 immune response		1
48	Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2022</b> , 9,	9.1	1
47	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2022</b> ,	5.4	1
46	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. <i>Blood</i> , <b>2020</b> , 136, 20-21	2.2	0
45	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal.. <i>Frontiers in Veterinary Science</i> , <b>2021</b> , 8, 755258	3.1	0
44	Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10007-10007	2.2	0
43	Establishing diagnostic criteria for mastocytosis in skin biopsies. <i>Histopathology</i> , <b>2021</b> , 80, 501	7.3	0
42	Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis. <i>Blood</i> , <b>2012</b> , 120, 4913-4913	2.2	0
41	Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). <i>American Journal of Hematology</i> , <b>2021</b> , 96, 834-845	7.1	0
40	Storage-Induced Micro-Erythrocytes Can Be Quantified and Sorted by Flow Cytometry.. <i>Frontiers in Physiology</i> , <b>2022</b> , 13, 838138	4.6	0
39	The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.. <i>Frontiers in Public Health</i> , <b>2022</b> , 10, 816848	6	0

38	Outcome of COVID-19 in Patients With Mantle Cell Lymphoma-Report From the European MCL Registry.. <i>HemaSphere</i> , <b>2022</b> , 6, e0711	0.3	0
37	Mast cell activation syndrome: High frequency of skin manifestations and anaphylactic shock. <i>Allergology International</i> , <b>2019</b> , 68, 119-121	4.4	
36	Reply to K. Ishitsuka et al. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, e766-e766	2.2	
35	Hypogammaglobulinemia during Rituximab Maintenance after Transplantation Is a Surrogate Marker for Disease Control in Patients with Mantle-Cell Lymphoma, an Analysis from the LyMa Trial. <i>Blood</i> , <b>2020</b> , 136, 42-42	2.2	
34	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , <b>2021</b> , 138, 3495-3495	2.2	
33	L-Asparaginase in the Treatment of Relapsing Nasal/Nasal Type NK-T-Cell Lymphoma.. <i>Blood</i> , <b>2004</b> , 104, 4598-4598	2.2	
32	Tax Ubiquitylation and Sumoylation Control the Two Distinct Steps of NF- $\kappa$ B Activation.. <i>Blood</i> , <b>2005</b> , 106, 4353-4353	2.2	
31	JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.. <i>Blood</i> , <b>2006</b> , 108, 4602-4602	2.2	
30	Molecular Mechanisms of NF-kappaB Activation by the HTLV-I Oncoprotein Tax: Role of Post Translational Protein Modification.. <i>Blood</i> , <b>2007</b> , 110, 4159-4159	2.2	
29	Targeted Therapy with Arsenic Trioxide and Interferon alpha Eradicates Leukemic Cells in SCID Mice Model of Adult T-Cell Leukemia/Lymphoma.. <i>Blood</i> , <b>2007</b> , 110, 1379-1379	2.2	
28	Complement System Activation after Allogeneic Bone Marrow Transplantation May Early Predict the Development of Acute Gastrointestinal GVHD.. <i>Blood</i> , <b>2007</b> , 110, 2186-2186	2.2	
27	Omalizumab: Efficacy and Safety in Mast Cell Disorders. <i>Blood</i> , <b>2018</b> , 132, 4280-4280	2.2	
26	Serotonin Targeting Using Common Antidepressants Induces Rapid Recovery of Cytopenia. <i>Blood</i> , <b>2019</b> , 134, 3715-3715	2.2	
25	French National Retrospective Cohort of Hairy-Cell Leukemias: Risk of Second Malignancies after 10 Years of Follow-up. <i>Blood</i> , <b>2019</b> , 134, 1537-1537	2.2	
24	Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator's choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS8622-TPS8622	2.2	
23	Minimal Residual Disease Monitoring By 8-Color Flow Cytometry in Mantle Cell Lymphoma Is Complementary to Q-PCR Monitoring and Will Facilitate Pre-Emptive Treatment: An EU-MCL and Lysa Study. <i>Blood</i> , <b>2014</b> , 124, 1657-1657	2.2	
22	Lymphoproliferative Disease in Wiskott-Aldrich Syndrome: Analysis of the French National Registry of Primary Immunodeficiencies. <i>Blood</i> , <b>2014</b> , 124, 4129-4129	2.2	
21	Masitinib plus carboplatin and gemcitabine for treatment of patients with advanced triple negative breast cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 1070-1070	2.2	

- 20 HSP70, the Key to Account for Erythroid Tropism of Diamond-Blackfan Anemia?. *Blood*, **2015**, 126, 671-671
- 19 Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma. *Blood*, **2015**, 126, 3993-3993
- 18 Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile. *Blood*, **2016**, 128, 2962-2962 2.2
- 17 Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. *Blood*, **2008**, 112, 1309-1309 2.2
- 16 Eight Colors Flow Cytometry Phenotyping for Blood Minimal Residual Disease Monitoring in Hairy Cell Leukaemia Patients.. *Blood*, **2009**, 114, 1609-1609 2.2
- 15 The Type of Enteropathy Is a Prognostic Factor in Enteropathy-Associated T-Cell Lymphoma.. *Blood*, **2009**, 114, 2937-2937 2.2
- 14 Prognostic Significance of Complement System Activation After Allogeneic Hematopoietic Stem Cell Transplantation.. *Blood*, **2009**, 114, 1166-1166 2.2
- 13 Association of Langerhans Cell Histiocytosis with Erdheim-Chester Disease: How Close Monocyte/Macrophage and Dendritic Cell Lineages Are?. *Blood*, **2010**, 116, 4716-4716 2.2
- 12 Favourable Outcome of B-Cell Non Hodgkin Lymphomas Associated with Hepatitis C Virus - ANRS HC13 LYMPHO-C Observational Study. *Blood*, **2010**, 116, 3116-3116 2.2
- 11 Polymeric Immunoglobulin A1 Controls Erythroblast Proliferation and Accelerates Erythropoiesis Recovery in Anemia. *Blood*, **2011**, 118, 679-679 2.2
- 10 Thalidomide in Advanced Mastocytosis. Results from an Open-Label, Multicentric, Phase II Study. *Blood*, **2011**, 118, 1754-1754 2.2
- 9 Masitinib in comparison to imatinib as first-line therapy of patients with advanced gastrointestinal stromal tumor (GIST): A randomized phase III trial.. *Journal of Clinical Oncology*, **2012**, 30, TPS10102-TPS10102 2.2
- 8 Heat Shock Protein 70 Cytosolic Sequestration by Excess of Free Alpha-Globin Chains Is a Key Mechanism of the Ineffective Erythropoiesis in  $\beta$ -Thalassemia Major Patients. *Blood*, **2012**, 120, 823-823 2.2
- 7 High Level of CD71 Expression On Neoplastic B Cells At Diagnosis Is Predictive of Overall Survival After Rituximab and Anthracyclines Based Regimen in Follicular Lymphoma. *Blood*, **2012**, 120, 1601-1601 2.2
- 6 Occurrence of Malignancies in Patients with Primary Immunodeficiencies: An Analysis of the French Primary Immunodeficiency Registry. *Blood*, **2012**, 120, 1057-1057 2.2
- 5 Iron Parameters and Relation To Prognosis In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. *Blood*, **2013**, 122, 2202-2202 2.2
- 4 Outcome Of Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma (ATL) Who Have Undergone Stem Cell Transplantation: A Retrospective Study Of The EBMT Lymphoma Working Party. *Blood*, **2013**, 122, 3398-3398 2.2
- 3 Phenotypic and Functional Characterization Of a Novel Immature Hematopoietic Myeloid Suppressive Progenitor Cells Mobilized By G-CSF. Application To Gvhd Treatment. *Blood*, **2013**, 122, 4476-4476 2.2

- 2 The Combination Of Arsenic, Interferon-Alpha, and Zidovudine Restores An Immunocompetent-like Micro-Environment In Patients With Adult T-Cell Leukemia/Lymphoma. *Blood*, **2013**, 122, 5100-5100 2.2
- 1 Prognostic Value Of Red Blood Cell and Platelet Transfusion In Elderly Patients With Aggressive Lymphoma Receiving First Line Immunochemotherapy: An Analysis Of The Lysa LNH 03-6B Study. *Blood*, **2013**, 122, 3663-3663 2.2